

CITATION REPORT

List of articles citing

Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics

DOI: 10.1007/s40262-015-0361-4
Clinical Pharmacokinetics, 2016, 55, 789-805.

Source: <https://exaly.com/paper-pdf/65553567/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
48	Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017 , 44, 277-290	2.7	21
47	Considerations for dosing immunoglobulin in obese patients. <i>Clinical and Experimental Immunology</i> , 2017 , 188, 353-362	6.2	22
46	Tumor necrosis factor inhibitors in psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 899-910	3.8	22
45	Impact of altered endogenous IgG on unspecific mAb clearance. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017 , 44, 351-374	2.7	5
44	Age and sex in drug development and testing for adults. <i>Pharmacological Research</i> , 2017 , 121, 83-93	10.2	34
43	Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 709-716	6.1	10
42	Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 962-975	3.8	14
41	[Therapeutic drug monitoring] 4th edition of the congress of pharmacology of anticancer drugs]. <i>Bulletin Du Cancer</i> , 2017 , 104, 800-806	2.4	0
40	Dual-Color Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor Antibodies. <i>Analytical Chemistry</i> , 2018 , 90, 3592-3599	7.8	32
39	Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile. <i>Scientific Reports</i> , 2018 , 8, 4797	4.9	13
38	Paper-Based Antibody Detection Devices Using Bioluminescent BRET-Switching Sensor Proteins. <i>Angewandte Chemie</i> , 2018 , 130, 15595-15599	3.6	15
37	Paper-Based Antibody Detection Devices Using Bioluminescent BRET-Switching Sensor Proteins. <i>Angewandte Chemie - International Edition</i> , 2018 , 57, 15369-15373	16.4	82
36	Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2059-2074	3.8	5
35	Large molecules with large pharmacokinetic variability: progress in pursuit of key considerations for intersubject variability. <i>International Journal of Pharmacokinetics</i> , 2018 , 3, 57-60	0.3	1
34	Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018 , 21, 130s-148s	3.4	27
33	A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K, K, endosome trafficking, and animal species. <i>MAbs</i> , 2018 , 10, 1322-1331	6.6	11
32	Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. <i>Clinical and Translational Science</i> , 2018 , 11, 540-552	4.9	80

31	Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 169-187	6.2	20
30	Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2721-2733	3.8	14
29	Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2045-2058	3.8	10
28	Peripheral and central nervous system distribution of the CGRP neutralizing antibody [I] galcanezumab in male rats. <i>Cephalalgia</i> , 2019 , 39, 1241-1248	6.1	41
27	Fluctuations in Pharmacokinetics Profiles of Monoclonal Antibodies. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019 , 44, 585-589	2.7	0
26	Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. <i>Antibodies</i> , 2019 , 8,	7	22
25	[Pharmacokinetic variability of therapeutic antibodies]. <i>Medecine/Sciences</i> , 2019 , 35, 1130-1136		
24	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e474-e484	14.2	583
23	Immunogenicity of TNF-Inhibitors. <i>Frontiers in Immunology</i> , 2020 , 11, 312	8.4	39
22	Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A PhaseII, Open-Label Study. <i>Rheumatology and Therapy</i> , 2020 , 7, 191-200	4.4	3
21	Immunogenicity of biologic agents in rheumatology. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 81-97	8.1	11
20	Anti-fouling poly adenine coating combined with highly specific CD20 epitope mimetic peptide for rituximab detection in clinical patients Tplasma. <i>Biosensors and Bioelectronics</i> , 2021 , 171, 112678	11.8	7
19	Eptinezumab. <i>Headache</i> , 2021 , 109-119	0.2	1
18	Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021 , 60, 4495-4507	3.9	3
17	Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
16	Estimation of Clearance and Bioavailability of Therapeutic Monoclonal Antibodies from Only Subcutaneous Injection Data in Humans Based on Comprehensive Analysis of Clinical Data. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1325-1334	6.2	1
15	Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1395-1406	6.2	2
14	Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data. <i>PLoS ONE</i> , 2021 , 16, e0258601	3.7	2

13	Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study.. <i>Biological and Pharmaceutical Bulletin</i> , 2022 , 45, 323-332	2.3	
12	SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.. <i>Digestive and Liver Disease</i> , 2022 ,	3.3	0
11	Optimal Physicochemical Properties of Antibody-Nanoparticle Conjugates for Improved Tumor Targeting.. <i>Advanced Materials</i> , 2022 , e2110305	24	6
10	Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial.. <i>Journal of Internal Medicine</i> , 2022 ,	10.8	1
9	Opportunities and Challenges for PBPK Model of mAbs in Paediatrics and Pregnancy. <i>AAPS Journal</i> , 2022 , 24,	3.7	1
8	Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars. 2022 , 14, 1766		2
7	Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars. Volume 16, 2803-2815		1
6	Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review. 13,		0
5	Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.		2
4	Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations.		0
3	Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.		1
2	Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose-escalation study. 2023 , 32, 161-170		0
1	Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial. 2023 , 178, 183-190		0